RM-032(RM-032) - 药物靶点：KRAS G12C x NRAS G12C_在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

KRAS G12C x NRAS G12C

作用机制

KRAS G12C抑制剂(KRAS G12C突变抑制剂)、NRAS G12C抑制剂(GTP酶NRAS G12C抑制剂)

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症-

原研机构

Revolution Medicines, Inc.

在研机构

Revolution Medicines, Inc.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 RM-032 相关的临床结果

登录后查看更多信息

100 项与 RM-032 相关的转化医学

登录后查看更多信息

100 项与 RM-032 相关的专利（医药）

登录后查看更多信息

1

项与 RM-032 相关的文献（医药）

2020-10-02·Bioscience, Biotechnology, and Biochemistry4区 · 工程技术

Actinomycins inhibit the production of the siderophore pyoverdines in the plant pathogen Pseudomonas cichorii SPC9018

4区 · 工程技术

Article

作者: Kai, Kenji ; Hikichi, Yasufumi ; Maenaka, Risa ; Tani, Shuji

AbstractPyoverdines, a group of peptide siderophores produced by Pseudomonas species, function not only in iron acquisition, but also in their virulence in hosts. Thus, chemical inhibition of pyoverdine production may be an effective strategy to control Pseudomonas virulence. In the plant pathogen Pseudomonas cichorii SPC9018 (SPC9018), pyoverdine production is required for virulence on eggplant. We screened microbial culture extracts in a pyoverdine-production inhibition assay of SPC9018 and found Streptomyces sp. RM-32 as a candidate-producer. We isolated two active compounds from RM-32 cultures, and elucidated their structures to be actinomycins X2 and D. Actinomycins X2 and D inhibited pyoverdine production by SPC9018 with IC50 values of 17.6 and 29.6 μM, respectively. Furthermore, pyoverdine production in other Pseudomonas bacteria, such as the mushroom pathogen P. tolaasii, was inhibited by the actinomycins. Therefore, these actinomycins may be useful as chemical tools to examine pyoverdine functions and as seed compounds for anti-Pseudomonas virulence agents.

100 项与 RM-032 相关的药物交易

登录后查看更多信息